Martin E Gleave

List of Publications by Year
in descending order

490 papers	42,738 citations	1792 103 h-index	3638 180 g-index
498 all docs	498 docs citations	498 times ranked	46680 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
2	Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. Cancer Discovery, 2011, 1, 487-495.	7.7	725
3	Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer. Cancer Research, 2008, 68, 6407-6415.	0.4	677
4	The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO Journal, 2011, 30, 2719-2733.	3.5	530
5	Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16170-16175.	3.3	513
6	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	0.9	488
7	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. Journal of Clinical Oncology, 2018, 36, 2492-2503.	0.8	477
8	Intraprostatic Androgens and Androgen-Regulated Gene Expression Persist after Testosterone Suppression: Therapeutic Implications for Castration-Resistant Prostate Cancer. Cancer Research, 2007, 67, 5033-5041.	0.4	474
9	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell, 2018, 174, 758-769.e9.	13.5	459
10	Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. International Journal of Cancer, 1994, 57, 406-412.	2.3	431
11	Active Surveillance of Small Renal Masses: Progression Patterns of Early Stage Kidney Cancer. European Urology, 2011, 60, 39-44.	0.9	422
12	Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells. Cancer Research, 2012, 72, 1878-1889.	0.4	421
13	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2015, 21, 2315-2324.	3.2	407
14	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discovery, 2018, 8, 444-457.	7.7	376
15	The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. Cell, 2013, 153, 1064-1079.	13.5	348
16	Antisense therapy for cancer. Nature Reviews Cancer, 2005, 5, 468-479.	12.8	341
17	Aggressive Variants of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2014, 20, 2846-2850.	3.2	339
18	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 3097-3104.	0.8	327

#	Article	IF	Citations
19	High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development. Cancer Research, 2014, 74, 1272-1283.	0.4	304
20	Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. JAMA Oncology, 2016, 2, 1598.	3.4	290
21	Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology, 1995, 45, 839-845.	0.5	289
22	Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 1998, 338, 1265-1271.	13.9	289
23	Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles. Oncotarget, 2015, 6, 11327-11341.	0.8	289
24	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	288
25	RANDOMIZED COMPARATIVE STUDY OF 3 VERSUS 8-MONTH NEOADJUVANT HORMONAL THERAPY BEFORE RADICAL PROSTATECTOMY: BIOCHEMICAL AND PATHOLOGICAL EFFECTS. Journal of Urology, 2001, 166, 500-507.	0.2	285
26	Heat Shock Protein 27 Increases after Androgen Ablation and Plays a Cytoprotective Role in Hormone-Refractory Prostate Cancer. Cancer Research, 2004, 64, 6595-6602.	0.4	285
27	The Master Neural Transcription Factor BRN2 Is an Androgen Receptorâ€“Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discovery, 2017, 7, 54-71.	7.7	285
28	Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nature Medicine, 2010, 16, 1414-1420.	15.2	280
29	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology, 2015, 26, 1589-1604.	0.6	279
30	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	0.9	278
31	Targeting <scp>ASCT2</scp>â€mediated glutamine uptake blocks prostate cancer growth and tumour development. Journal of Pathology, 2015, 236, 278-289.	2.1	275
32	A Phase I Pharmacokinetic and Pharmacodynamic Study of OGX-011, a 2â€²-Methoxyethyl Antisense Oligonucleotide to Clusterin, in Patients With Localized Prostate Cancer. Journal of the National Cancer Institute, 2005, 97, 1287-1296.	3.0	264
33	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncology, 2015, 1, 466.	3.4	264
34	Dysregulation of Sterol Response Element-Binding Proteins and Downstream Effectors in Prostate Cancer during Progression to Androgen Independence. Cancer Research, 2004, 64, 2212-2221.	0.4	250
35	Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell, 2004, 5, 79-90.	7.7	249
36	Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncology, The, 2019, 20, 1730-1739.	5.1	227

#	Article	IF	Citations
37	Cooperative Interactions between Androgen Receptor (AR) and Heat-Shock Protein 27 Facilitate AR Transcriptional Activity. Cancer Research, 2007, 67, 10455-10465.	0.4	224
38	YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. Journal of Cell Biology, 2015, 208, 913-929.	2.3	224
39	Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 4247-4254.	0.8	221
40	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. Cell Reports, 2015, 12, 922-936.	2.9	216
41	Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate, 2002, 50, 179-188.	1.2	215
42	Reproducibility and efficiency of serum-derived exosome extraction methods. Clinical Biochemistry, 2014, 47, 1286-1292.	0.8	215
43	Increased Hsp27 after Androgen Ablation Facilitates Androgen-Independent Progression in Prostate Cancer via Signal Transducers and Activators of Transcription 3â€“Mediated Suppression of Apoptosis. Cancer Research, 2005, 65, 11083-11093.	0.4	204
44	Insulin receptor expression by human prostate cancers. Prostate, 2009, 69, 33-40.	1.2	203
45	Assessing Information and Decision Preferences of Men With Prostate Cancer and Their Partners. Cancer Nursing, 2002, 25, 42-49.	0.7	202
46	The DNA methylation landscape of advanced prostate cancer. Nature Genetics, 2020, 52, 778-789.	9.4	198
47	Silencing Expression of the Clusterin/Apolipoprotein J Gene in Human Cancer Cells Using Small Interfering RNA Induces Spontaneous Apoptosis, Reduced Growth Ability, and Cell Sensitization to Genotoxic and Oxidative Stress. Cancer Research, 2004, 64, 1834-1842.	0.4	195
48	Deep Docking: A Deep Learning Platform for Augmentation of Structure Based Drug Discovery. ACS Central Science, 2020, 6, 939-949.	5.3	195
49	Molecular Profiling Identifies Prognostic Subgroups of Pediatric Glioblastoma and Shows Increased YB-1 Expression in Tumors. Journal of Clinical Oncology, 2007, 25, 1196-1208.	0.8	187
50	Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. Journal of Steroid Biochemistry and Molecular Biology, 1996, 58, 139-146.	1.2	184
51	Androgenic Induction of Prostate-specific Antigen Gene Is Repressed by Protein-Protein Interaction between the Androgen Receptor and AP-1/c-Jun in the Human Prostate Cancer Cell Line LNCaP. Journal of Biological Chemistry, 1997, 272, 17485-17494.	1.6	184
52	Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2013, 31, 1740-1747.	0.8	184
53	MicroRNAs Associated with Metastatic Prostate Cancer. PLoS ONE, 2011, 6, e24950.	1.1	183
54	Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer. Cancer Research, 2013, 73, 3109-3119.	0.4	182

#	Article	IF	Citations
55	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repairâ€“deficient Prostate Cancer. European Urology, 2017, 72, 34-42.	0.9	179
56	Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer With the Use of Antisense Bcl-2 Oligodeoxynucleotides. Journal of the National Cancer Institute, 2000, 92, 34-41.	3.0	178
57	Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Molecular Cancer Therapeutics, 2007, 6, 299-308.	1.9	176
58	Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional Collaboration. European Urology, 2011, 60, 205-210.	0.9	175
59	The 44-kDa Pim-1 Kinase Phosphorylates BCRP/ABCG2 and Thereby Promotes Its Multimerization and Drug-resistant Activity in Human Prostate Cancer Cells. Journal of Biological Chemistry, 2008, 283, 3349-3356.	1.6	167
60	A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 2005, 11, 3854-3861.	3.2	166
61	Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biology, 2016, 17, 10.	3.8	165
62	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. Journal of Pathology, 2012, 227, 286-297.	2.1	161
63	Biochemical and Pathological Effects of 8 Months of Neoadjuvant Androgen Withdrawal Therapy Before Radical Prostatectomy in Patients with Clinically Confined Prostate Cancer. Journal of Urology, 1996, 155, 213-219.	0.2	158
64	Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer. Clinical Cancer Research, 2007, 13, 1493-1502.	3.2	157
65	Towards precision oncology in advanced prostate cancer. Nature Reviews Urology, 2019, 16, 645-654.	1.9	156
66	NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell, 2006, 9, 367-378.	7.7	155
67	Small heat shock proteins in cancer therapy and prognosis. International Journal of Biochemistry and Cell Biology, 2012, 44, 1646-1656.	1.2	153
68	Increased Insulin-Like Growth Factor I Receptor Expression and Signaling Are Components of Androgen-Independent Progression in a Lineage-Derived Prostate Cancer Progression Model. Cancer Research, 2004, 64, 8620-8629.	0.4	148
69	YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate, 2004, 59, 337-349.	1.2	147
70	Targeting Amino Acid Transport in Metastatic Castration-Resistant Prostate Cancer: Effects on Cell Cycle, Cell Growth, and Tumor Development. Journal of the National Cancer Institute, 2013, 105, 1463-1473.	3.0	147
71	Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. European Urology, 2015, 68, 228-235.	0.9	144
72	ONECUT2 is a driver of neuroendocrine prostate cancer. Nature Communications, 2019, 10, 278.	5.8	143

#	Article	IF	Citations
73	Overexpression of Insulin-Like Growth Factor Binding Protein-5 Helps Accelerate Progression to Androgen-Independence in the Human Prostate LNCaP Tumor Model through Activation of Phosphatidylinositol 3â€²-Kinase Pathway*. Endocrinology, 2000, 141, 2257-2265.	1.4	138
74	Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers. Nature Communications, 2018, 9, 4080.	5.8	138
75	Mechanisms of the development of androgen independence in prostate cancer. World Journal of Urology, 2005, 23, 1-9.	1.2	137
76	SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. European Urology, 2017, 71, 68-78.	0.9	136
77	Intake of Selenium in the Prevention of Prostate Cancer: a Systematic Review and Meta-analysis*. Cancer Causes and Control, 2005, 16, 1125-1131.	0.8	135
78	Clusterin Mediates TGF-Î²â€“Induced Epithelialâ€“Mesenchymal Transition and Metastasis via Twist1 in Prostate Cancer Cells. Cancer Research, 2012, 72, 5261-5272.	0.4	135
79	Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study. Clinical Cancer Research, 2013, 19, 2442-2450.	3.2	132
80	The E3ÂUbiquitin Ligase Siah2 Contributes to Castration-Resistant Prostate Cancer by Regulation of Androgen Receptor Transcriptional Activity. Cancer Cell, 2013, 23, 332-346.	7.7	132
81	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. European Urology, 2019, 75, 667-675.	0.9	131
82	New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety. European Urology, 2011, 60, 279-290.	0.9	130
83	In vivo Knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors. Clinical Cancer Research, 2009, 15, 39-47.	3.2	125
84	Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 776-787.	3.3	124
85	Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer. Clinical Cancer Research, 2010, 16, 1088-1093.	3.2	123
86	Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer. International Journal of Molecular Sciences, 2013, 14, 7757-7770.	1.8	122
87	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. Journal of Urology, 2016, 195, 313-320.	0.2	122
88	Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c. Clinical Cancer Research, 2011, 17, 5765-5773.	3.2	120
89	Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer ProgressionIn Vivo. Molecular Cancer Therapeutics, 2013, 12, 2342-2355.	1.9	120
90	Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology, 1996, 47, 708-712.	0.5	118

#	Article	IF	Citations
91	Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting the Antiapoptotic Gene Clusterin. Neoplasia, 2001, 3, 360-367.	2.3	116
92	Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU International, 2006, 98, 1082-1089.	1.3	116
93	PAMAM Dendrimers Mediate siRNA Delivery to Target Hsp27 and Produce Potent Antiproliferative Effects on Prostate Cancer Cells. ChemMedChem, 2009, 4, 1302-1310.	1.6	116
94	Clusterin Facilitates COMMD1 and I-ÎºB Degradation to Enhance NF-ÎºB Activity in Prostate Cancer Cells. Molecular Cancer Research, 2010, 8, 119-130.	1.5	115
95	Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clinical Cancer Research, 2002, 8, 3276-84.	3.2	115
96	Expression and Nuclear Localization of ErbB3 in Prostate Cancer. Clinical Cancer Research, 2006, 12, 2730-2737.	3.2	114
97	A Phase I Study of OGX-011, a 2â€²-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer. Clinical Cancer Research, 2008, 14, 833-839.	3.2	114
98	Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment. European Urology, 2014, 65, 289-299.	0.9	113
99	Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy Before Radical Prostatectomy for Patients With High Risk Localized Prostate Cancer. Journal of Urology, 2008, 180, 565-570.	0.2	112
100	Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4251-4256.	3.3	110
101	Targeting the adaptive molecular landscape of castrationâ€resistant prostate cancer. EMBO Molecular Medicine, 2015, 7, 878-894.	3.3	110
102	Clinical and molecular features of treatmentâ€related neuroendocrine prostate cancer. International Journal of Urology, 2018, 25, 345-351.	0.5	110
103	Clusterin knockdown using the antisense oligonucleotide OGXâ€011 reâ€sensitizes docetaxelâ€refractory prostate cancer PCâ€3 cells to chemotherapy. BJU International, 2008, 102, 389-397.	1.3	109
104	Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth. Clinical Cancer Research, 2015, 21, 1675-1687.	3.2	108
105	Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized. American Journal of Surgical Pathology, 2016, 40, 1439-1456.	2.1	107
106	AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate. Journal of Urology, 2017, 197, 135-142.	0.2	106
107	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 2018, 73, 715-723.	0.9	105
108	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 76, 562-571.	0.9	104

#	Article	IF	Citations
109	Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology, 1999, 54, 36-46.	0.5	103
110	Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU International, 2011, 108, E202-E210.	1.3	103
111	Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival. Nature Communications, 2014, 5, 5775.	5.8	101
112	A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Molecular Cancer Therapeutics, 2005, 4, 1689-1698.	1.9	98
113	Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer. Cancer, 2006, 107, 389-395.	2.0	98
114	Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. International Journal of Cancer, 2001, 91, 846-850.	2.3	97
115	Insulin Increases De Novo Steroidogenesis in Prostate Cancer Cells. Cancer Research, 2011, 71, 5754-5764.	0.4	97
116	GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer. Oncogene, 2013, 32, 1933-1942.	2.6	97
117	Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology, 2002, 59, 150-154.	0.5	95
118	Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation. FASEB Journal, 2013, 27, 1549-1560.	0.2	95
119	A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo. Molecular Cancer Therapeutics, 2013, 12, 567-576.	1.9	94
120	Extracellular HSP27 mediates angiogenesis through Tollâ€like receptor 3. FASEB Journal, 2013, 27, 4169-4183.	0.2	93
121	Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World Journal of Urology, 2005, 23, 38-46.	1.2	92
122	Identification of CD166 as a Surface Marker for Enriching Prostate Stem/Progenitor and Cancer Initiating Cells. PLoS ONE, 2012, 7, e42564.	1.1	91
123	Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. European Urology, 2015, 67, 986-990.	0.9	91
124	Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Research, 2003, 63, 3575-84.	0.4	90
125	Human prostate cancer model: Roles of growth factors and extracellular matrices. Journal of Cellular Biochemistry, 1992, 50, 99-105.	1.2	89
126	Protein Profiling of Microdissected Prostate Tissue Links Growth Differentiation Factor 15 to Prostate Carcinogenesis. Cancer Research, 2004, 64, 5929-5933.	0.4	89

#	Article	IF	Citations
127	Phase 3, randomized, placeboâ€controlled study of zibotentan (ZD4054) in patients with castrationâ€resistant prostate cancer metastatic to bone. Cancer, 2012, 118, 5709-5718.	2.0	89
128	DJ-1 Binds Androgen Receptor Directly and Mediates Its Activity in Hormonally Treated Prostate Cancer Cells. Cancer Research, 2007, 67, 4630-4637.	0.4	88
129	Targeting heat shock proteins in metastatic castration-resistant prostate cancer. Nature Reviews Urology, 2015, 12, 26-36.	1.9	88
130	BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. Genome Medicine, 2019, 11, 8.	3.6	88
131	ASAP1, a Gene at 8q24, Is Associated with Prostate Cancer Metastasis. Cancer Research, 2008, 68, 4352-4359.	0.4	87
132	OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death and Disease, 2011, 2, e221-e221.	2.7	87
133	The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. International Journal of Cancer, 2015, 136, E27-38.	2.3	87
134	Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival. Oncogene, 2016, 35, 2441-2452.	2.6	87
135	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12315-12323.	3.3	87
136	Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363. Clinical Cancer Research, 2013, 19, 833-844.	3.2	86
137	Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2015, 14, 59-69.	1.9	85
138	Clusterin Inhibition Using OGX-011 Synergistically Enhances Hsp90 Inhibitor Activity by Suppressing the Heat Shock Response in Castrate-Resistant Prostate Cancer. Cancer Research, 2011, 71, 5838-5849.	0.4	84
139	TheMCT4Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer. Clinical Cancer Research, 2016, 22, 2721-2733.	3.2	84
140	A Prospective Study on ¹⁸F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1587-1593.	2.8	84
141	Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Molecular Cancer Therapeutics, 2005, 4, 1837-1849.	1.9	83
142	Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. Journal of Clinical Oncology, 2019, 37, 3090-3098.	0.8	81
143	Neoadjuvant Enzalutamide Prior to Prostatectomy. Clinical Cancer Research, 2017, 23, 2169-2176.	3.2	80
144	Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Molecular Cancer Therapeutics, 2004, 3, 223-32.	1.9	80

#	Article	IF	Citations
145	Class I <scp>HDAC</scp> inhibitors enhance <scp>YB</scp> â€1 acetylation and oxidative stress to block sarcoma metastasis. EMBO Reports, 2019, 20, e48375.	2.0	78
146	Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology, 2001, 58, 39-48.	0.5	77
147	A molecular portrait of epithelialâ€"mesenchymal plasticity in prostate cancer associated with clinical outcome. Oncogene, 2019, 38, 913-934.	2.6	76
148	Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2016, 22, 670-679.	3.2	75
149	Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). European Urology, 2018, 73, 4-8.	0.9	75
150	Hsp27 Promotes Insulin-Like Growth Factor-I Survival Signaling in Prostate Cancer via p90Rsk-Dependent Phosphorylation and Inactivation of BAD. Cancer Research, 2010, 70, 2307-2317.	0.4	74
151	Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 579-586.	0.5	74
152	A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. Annals of Oncology, 2016, 27, 1116-1122.	0.6	74
153	Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate, 2004, 61, 318-323.	1.2	73
154	Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU International, 2009, 103, 978-986.	1.3	73
155	Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4584-E4593.	3.3	73
156	Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. European Urology, 2016, 69, 775-787.	0.9	72
157	An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nature Cell Biology, 2021, 23, 1023-1034.	4.6	72
158	Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer. Clinical Cancer Research, 2008, 14, 6944-6954.	3.2	71
159	Targeting TCTP as a New Therapeutic Strategy in Castration-resistant Prostate Cancer. Molecular Therapy, 2012, 20, 2244-2256.	3.7	71
160	Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biology, 2014, 15, 426.	3.8	71
161	Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Modern Pathology, 2016, 29, 904-914.	2.9	71
162	A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancer. World Journal of Urology, 2018, 36, 215-220.	1.2	71

#	Article	IF	Citations
163	Loss of PTEN is associated with progression to androgen independence. Prostate, 2006, 66, 895-902.	1.2	70
164	Canary Prostate Active Surveillance Study: Design of a Multi-institutional Active Surveillance Cohort and Biorepository. Urology, 2010, 75, 407-413.	0.5	70
165	Progression From High-Grade Prostatic Intraepithelial Neoplasia to Cancer: A Randomized Trial of Combination Vitamin-E, Soy, and Selenium. Journal of Clinical Oncology, 2011, 29, 2386-2390.	0.8	70
166	Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer. European Urology, 2014, 66, 145-155.	0.9	70
167	Expression and Function of the Progesterone Receptor in Human Prostate Stroma Provide Novel Insights to Cell Proliferation Control. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2887-2896.	1.8	69
168	Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clinical Cancer Research, 2017, 23, 6802-6811.	3.2	69
169	Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene, 2017, 36, 3417-3427.	2.6	68
170	Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. Lancet Oncology, The, 2017, 18, 473-485.	5.1	67
171	Comparing a Generic and Individualized Information Decision Support Intervention for Men Newly Diagnosed With Localized Prostate Cancer. Cancer Nursing, 2007, 30, E7-E15.	0.7	66
172	Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. BJU International, 2012, 109, 660-664.	1.3	66
173	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 531-538.	2.0	66
174	The Insulin-Like Growth Factor I Receptor Is Required for Akt Activation and Suppression of Anoikis in Cells Transformed by the ETV6-NTRK3 Chimeric Tyrosine Kinase. Molecular and Cellular Biology, 2006, 26, 1754-1769.	1.1	65
175	Differential Regulation of Clusterin and Its Isoforms by Androgens in Prostate Cells. Journal of Biological Chemistry, 2007, 282, 2278-2287.	1.6	64
176	Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability. Cancer Research, 2013, 73, 5206-5217.	0.4	64
177	The <scp>M</scp>elbourne Consensus Statement on the early detection of prostate cancer. BJU International, 2014, 113, 186-188.	1.3	64
178	Timing Is Everything: Preclinical Evidence Supporting Simultaneous Rather Than Sequential Chemohormonal Therapy for Prostate Cancer. Clinical Cancer Research, 2005, 11, 4905-4911.	3.2	63
179	Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU International, 2006, 97, 1300-1308.	1.3	63
180	A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU International, 2007, 100, 1377-1384.	1.3	63

#	Article	IF	Citations
181	Clusterin Is a Critical Downstream Mediator of Stress-Induced YB-1 Transactivation in Prostate Cancer. Molecular Cancer Research, 2011, 9, 1755-1766.	1.5	63
182	Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. Journal of Pathology, 2012, 227, 53-61.	2.1	63
183	GLI2 Knockdown Using an Antisense Oligonucleotide Induces Apoptosis and Chemosensitizes Cells to Paclitaxel in Androgen-Independent Prostate Cancer. Clinical Cancer Research, 2008, 14, 5769-5777.	3.2	62
184	Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2013, 16, 187-192.	2.0	62
185	Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. , 2000, 86, 855-862.		61
186	The ability of prostateâ€specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. BJU International, 2012, 110, 36-42.	1.3	61
187	The Mechanism of DAB2IP in Chemoresistance of Prostate Cancer Cells. Clinical Cancer Research, 2013, 19, 4740-4749.	3.2	61
188	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. European Urology, 2017, 72, 448-454.	0.9	61
189	siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer. Clinical Cancer Research, 2015, 21, 4845-4855.	3.2	60
190	Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33. Scientific Reports, 2016, 6, 30555.	1.6	60
191	PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. European Urology Focus, 2016, 2, 180-188.	1.6	60
192	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. European Urology, 2018, 73, 524-532.	0.9	60
193	Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. European Urology, 2019, 75, 940-947.	0.9	60
194	LIN28B promotes the development of neuroendocrine prostate cancer. Journal of Clinical Investigation, 2020, 130, 5338-5348.	3.9	60
195	Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. Urology, 2000, 56, 289-294.	0.5	59
196	Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer. Molecular Cancer Therapeutics, 2012, 11, 1661-1671.	1.9	59
197	Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors. Prostate, 2000, 44, 156-163.	1.2	58
198	Hsp27 regulates EGF/Î²â€catenin mediated epithelial to mesenchymal transition in prostate cancer. International Journal of Cancer, 2015, 136, E496-507.	2.3	58

#	Article	IF	Citations
199	Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget, 2015, 6, 14318-14328.	0.8	58
200	Cyclin G-associated kinase: A novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. International Journal of Cancer, 2006, 118, 1108-1119.	2.3	57
201	Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo. Molecular Cancer Therapeutics, 2011, 10, 347-359.	1.9	57
202	A Novel HSP90 Inhibitor Delays Castrate-Resistant Prostate Cancer without Altering Serum PSA Levels and Inhibits Osteoclastogenesis. Clinical Cancer Research, 2011, 17, 2301-2313.	3.2	57
203	Therapeutic options for hormone-refractory prostate cancer in 2007. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 413-419.	0.8	56
204	Heat Shock Protein 27 as a New Therapeutic Target for Radiation Sensitization of Head and Neck Squamous Cell Carcinoma. Molecular Therapy, 2009, 17, 1387-1394.	3.7	56
205	The novel BETâ€CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wildâ€type prostate cancer. EMBO Molecular Medicine, 2019, 11, e10659.	3.3	56
206	GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget, 2014, 5, 451-461.	0.8	56
207	Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals. Nuclear Medicine and Biology, 2008, 35, 875-882.	0.3	55
208	Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists. Journal of Medicinal Chemistry, 2011, 54, 7693-7704.	2.9	55
209	A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate, 2015, 75, 1206-1215.	1.2	55
210	Relationship of clusterin with renal inflammation and fibrosis after the recovery phase of ischemia-reperfusion injury. BMC Nephrology, 2016, 17, 133.	0.8	55
211	Targeting <scp>MCT</scp>4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer. Cancer Medicine, 2018, 7, 3385-3392.	1.3	55
212	<scp>SEMA</scp> 3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. EMBO Molecular Medicine, 2018, 10, 219-238.	3.3	54
213	The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. GigaScience, 2018, 7, .	3.3	54
214	Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28. Molecular Cell, 2020, 77, 970-984.e7.	4.5	54
215	Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens. Prostate, 2006, 66, 1698-1709.	1.2	52
216	In vivo Evaluation of Mucoadhesive Nanoparticulate Docetaxel for Intravesical Treatment of Nonâ€“Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2011, 17, 2788-2798.	3.2	52

#	Article	IF	Citations
217	Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies. Prostate Cancer and Prostatic Diseases, 2016, 19, 264-270.	2.0	52
218	Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro. Experimental Cell Research, 2005, 310, 99-104.	1.2	51
219	Slug, a Unique Androgen-Regulated Transcription Factor, Coordinates Androgen Receptor to Facilitate Castration Resistance in Prostate Cancer. Molecular Endocrinology, 2012, 26, 1496-1507.	3.7	51
220	Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Molecular Cancer Research, 2019, 17, 1235-1240.	1.5	51
221	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nature Communications, 2021, 12, 7349.	5.8	51
222	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	0.9	51
223	Multiparametric Magnetic Resonance Imaging Enhances Detection of Significant Tumor in Patients on Active Surveillance for Prostate Cancer. Urology, 2015, 85, 423-429.	0.5	50
224	Stress-induced tunneling nanotubes support treatment adaptation in prostate cancer. Scientific Reports, 2019, 9, 7826.	1.6	50
225	Intravesically administered antisense oligonucleotides targeting heatâ€shock proteinâ€27 inhibit the growth of nonâ€muscleâ€invasive bladder cancer. BJU International, 2008, 102, 610-616.	1.3	49
226	Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. Journal of Steroid Biochemistry and Molecular Biology, 2009, 115, 126-136.	1.2	49
227	Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Prostate Cancers following Therapy with LH-RH Agonists. Clinical Cancer Research, 2010, 16, 4675-4680.	3.2	49
228	Promotion of cell proliferation by clusterin in the renal tissue repair phase after ischemia-reperfusion injury. American Journal of Physiology - Renal Physiology, 2014, 306, F724-F733.	1.3	49
229	Introducing the Clusterin Gene Into Human Renal Cell Carcinoma Cells Enhances Their Metastatic Potential. Journal of Urology, 2002, 167, 2203-2208.	0.2	48
230	Oncolytic Vesicular Stomatitis Viruses Are Potent Agents for Intravesical Treatment of High-Risk Bladder Cancer. Cancer Research, 2008, 68, 4506-4510.	0.4	48
231	Loss of clusterin expression worsens renal ischemia-reperfusion injury. American Journal of Physiology - Renal Physiology, 2010, 298, F568-F578.	1.3	48
232	The importance of integrinâ€linked kinase in the regulation of bladder cancer invasion. International Journal of Cancer, 2012, 130, 521-531.	2.3	48
233	IGF2 increases de novo steroidogenesis in prostate cancer cells. Endocrine-Related Cancer, 2013, 20, 173-186.	1.6	48
234	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canaryâ€“Early Detection Research Network Active Surveillance Biopsy Risk Calculator. European Urology, 2015, 68, 1083-1088.	0.9	48

#	Article	IF	Citations
235	Integrated analysis of the prostate cancer smallâ€nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. Molecular Oncology, 2016, 10, 693-703.	2.1	48
236	Heterochromatin Protein 1Î± Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer. Cancer Research, 2018, 78, 2691-2704.	0.4	48
237	Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. European Urology, 2019, 75, 44-60.	0.9	48
238	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. Journal of Clinical Oncology, 2020, 38, 1549-1557.	0.8	48
239	Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. International Journal of Urology, 2005, 12, 785-794.	0.5	47
240	A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer. Clinical Cancer Research, 2012, 18, 3407-3413.	3.2	47
241	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. European Urology, 2020, 78, 834-844.	0.9	47
242	Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget, 2017, 8, 18949-18967.	0.8	47
243	Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Prostate, 2010, 70, 239-251.	1.2	46
244	Polyâ€gene fusion transcripts and chromothripsis in prostate cancer. Genes Chromosomes and Cancer, 2012, 51, 1144-1153.	1.5	46
245	Molecular model for neuroendocrine prostate cancer progression. BJU International, 2018, 122, 560-570.	1.3	46
246	Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch. Cell Death and Differentiation, 2012, 19, 990-1002.	5.0	45
247	Canadian guidelines for the management of the small renal mass (SRM). Canadian Urological Association Journal, 2015, 9, 160.	0.3	45
248	The role of DAB2IP in androgen receptor activation during prostate cancer progression. Oncogene, 2014, 33, 1954-1963.	2.6	44
249	Growth kinetics of small renal masses: A prospective analysis from the Renal Cell Carcinoma Consortium of Canada. Canadian Urological Association Journal, 2014, 8, 24.	0.3	44
250	Acquisition of Resistance to Fas-Mediated Apoptosis by Overexpression of Clusterin in Human Renal-Cell Carcinoma Cells. Molecular Urology, 2001, 5, 105-111.	1.0	43
251	Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opinion on Investigational Drugs, 2008, 17, 1955-1962.	1.9	43
252	Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer. Journal of Urology, 2012, 188, 103-109.	0.2	43

#	Article	IF	Citations
253	TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. International Journal of Cancer, 2013, 133, 1955-1966.	2.3	43
254	Hsp27 Inhibition with OGX-427 Sensitizes Nonâ€“Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy. Molecular Cancer Therapeutics, 2015, 14, 1107-1116.	1.9	43
255	Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling. Cell Communication and Signaling, 2019, 17, 120.	2.7	43
256	A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. Nature Communications, 2021, 12, 1521.	5.8	43
257	AR-v7 protein expression is regulated by protein kinase and phosphatase. Oncotarget, 2015, 6, 33743-33754.	0.8	43
258	Clusterin and IGFBPs as Antisense Targets in Prostate Cancer. Annals of the New York Academy of Sciences, 2003, 1002, 95-104.	1.8	41
259	Clusterin Regulates Drug-Resistance in Melanoma Cells. Journal of Investigative Dermatology, 2005, 124, 1300-1307.	0.3	41
260	Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemotherapy and Pharmacology, 2005, 56, 47-57.	1.1	41
261	PTEN Loss Promotes Mitochondrially Dependent Type II Fas-Induced Apoptosis via PEA-15. Molecular and Cellular Biology, 2009, 29, 1222-1234.	1.1	41
262	Molecular Decoy to the Y-Box Binding Protein-1 Suppresses the Growth of Breast and Prostate Cancer Cells whilst Sparing Normal Cell Viability. PLoS ONE, 2010, 5, e12661.	1.1	41
263	Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1984-1993.	1.1	41
264	G3BP1-linked mRNA partitioning supports selective protein synthesis in response to oxidative stress. Nucleic Acids Research, 2020, 48, 6855-6873.	6.5	41
265	High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 385-389.	3.3	41
266	Androgens and prostate cancer. World Journal of Urology, 2003, 21, 325-337.	1.2	40
267	SYNERGISTIC ANTITUMOR ACTIVITY BY COMBINED TREATMENT WITH GEMCITABINE AND ANTISENSE OLIGODEOXYNUCLEOTIDE TARGETING CLUSTERIN GENE IN AN INTRAVESICAL ADMINISTRATION MODEL AGAINST HUMAN BLADDER CANCER KOTCC-1 CELLS. Journal of Urology, 2004, 171, 2477-2481.	0.2	40
268	The Role of Stress Proteins in Prostate Cancer. Current Genomics, 2007, 8, 252-261.	0.7	40
269	Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. European Journal of Cancer, 2009, 45, 1846-1854.	1.3	40
270	Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. Oncotarget, 2015, 6, 1806-1820.	0.8	40

#	Article	IF	Citations
271	Introduction ofClusterinGene into Human Renal Cell Carcinoma Cells Enhances Their Resistance to Cytotoxic Chemotherapy through Inhibition of Apoptosis bothin vitroandin vivo. Japanese Journal of Cancer Research, 2001, 92, 1220-1224.	1.7	39
272	Inhibition of the Phosphatidylinositol 3â€²-Kinase Pathway Promotes Autocrine Fas-Induced Death of Phosphatase and Tensin Homologueâ€“Deficient Prostate Cancer Cells. Cancer Research, 2006, 66, 4781-4788.	0.4	39
273	Knock-down of the Cytoprotective Gene, Clusterin, to Enhance Hormone and Chemosensitivity in Prostate and Other Cancers. Annals of the New York Academy of Sciences, 2005, 1058, 1-15.	1.8	38
274	Antisense clusterin oligodeoxynucleotides increase the response ofHER-2 gene amplified breast cancer cells to Trastuzumab. Journal of Cellular Physiology, 2005, 204, 463-469.	2.0	38
275	Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer. BJU International, 2008, 101, 1347-1355.	1.3	38
276	Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer. Molecular Cancer Therapeutics, 2009, 8, 2402-2411.	1.9	38
277	Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. European Journal of Medicinal Chemistry, 2018, 160, 108-119.	2.6	38
278	Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer. Oncotarget, 2015, 6, 9086-9098.	0.8	38
279	Crosstalk Between Nuclear MET and SOX9/Î²-Catenin Correlates with Castration-Resistant Prostate Cancer. Molecular Endocrinology, 2014, 28, 1629-1639.	3.7	37
280	The Tyrphostin NT157 Suppresses Insulin Receptor Substrates and Augments Therapeutic Response of Prostate Cancer. Molecular Cancer Therapeutics, 2014, 13, 2827-2839.	1.9	37
281	UGT2B17 Expedites Progression of Castration-Resistant Prostate Cancers by Promoting Ligand-Independent AR Signaling. Cancer Research, 2016, 76, 6701-6711.	0.4	37
282	A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy. Clinical Cancer Research, 2017, 23, 1974-1980.	3.2	37
283	A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. Investigational New Drugs, 2018, 36, 278-287.	1.2	37
284	Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. Oncotarget, 2017, 8, 42438-42454.	0.8	37
285	Control of tumor progression by maintenance of apoptosis. Prostate, 1996, 29, 13-21.	1.2	36
286	Differential transactivation by the androgen receptor in prostate cancer cells. , 1998, 36, 256-263.		36
287	p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer. Cancer Research, 2020, 80, 3074-3087.	0.4	36
288	Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. European Urology, 2021, 79, 16-19.	0.9	36

#	Article	IF	Citations
289	Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models. Journal of Clinical Investigation, 2019, 130, 699-714.	3.9	36
290	Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncology Reports, 2003, 10, 469-73.	1.2	36
291	Antisense therapy: current status in prostate cancer and other malignancies. Cancer and Metastasis Reviews, 2002, 21, 79-92.	2.7	35
292	Antisense oligonucleotide targeting of insulinâ€like growth factorâ€1 receptor (IGFâ€1R) in prostate cancer. Prostate, 2010, 70, 206-218.	1.2	35
293	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis, 2018, 39, 1431-1437.	1.3	35
294	The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth. Oncotarget, 2014, 5, 6425-6436.	0.8	35
295	Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. Cancer Chemotherapy and Pharmacology, 2005, 56, 239-247.	1.1	34
296	Comprehensive expression analysis of l-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Human Pathology, 2007, 38, 161-170.	1.1	34
297	Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target. Molecular Cancer Therapeutics, 2012, 11, 775-783.	1.9	34
298	Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation. Prostate, 2015, 75, 1043-1050.	1.2	34
299	Multiparametric magnetic resonance imagingâ€“targeted biopsy for the detection of prostate cancer in patients with prior negative biopsy results. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 165.e1-165.e7.	0.8	34
300	The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression. Translational Oncology, 2012, 5, 453-460.	1.7	33
301	Semaphorin 3â€‰C drives epithelial-to-mesenchymal transition, invasiveness, and stem-like characteristics in prostate cells. Scientific Reports, 2017, 7, 11501.	1.6	33
302	BIRC6 Protein, an Inhibitor of Apoptosis: Role in Survival of Human Prostate Cancer Cells. PLoS ONE, 2013, 8, e55837.	1.1	33
303	Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncology Reports, 2005, 14, 1371-5.	1.2	33
304	Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity. International Journal of Urology, 2001, 8, 337-349.	0.5	32
305	Clusterin as a therapeutic target for radiation sensitization in a lung cancer model. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1228-1236.	0.4	32
306	Therapeutic Efficacy of Adenoviral-Mediated p53 Gene Transfer Is Synergistically Enhanced by Combined Use of Antisense Oligodeoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model. Neoplasia, 2005, 7, 171-179.	2.3	32

#	Article	IF	Citations
307	Expression of clusterin in prostate cancer correlates with gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy. Urology, 2006, 68, 609-614.	0.5	32
308	Targeting prostate cancer with HTIâ€286, a synthetic analog of the marine sponge product hemiasterlin. International Journal of Cancer, 2008, 122, 2368-2376.	2.3	32
309	Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer. Current Drug Targets, 2003, 4, 209-221.	1.0	32
310	Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model. , 1998, 69, 271-281.		31
311	The inhibition of angiogenesis by antisense oligonucleotides to clusterin. Angiogenesis, 2005, 8, 229-238.	3.7	31
312	High-Risk Localized Prostate Cancer: A Case for Early Chemotherapy. Journal of Clinical Oncology, 2005, 23, 8186-8191.	0.8	31
313	The continued debate: Intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 81-86.	0.8	31
314	Tissue uptake of docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and their effects on the morphology of the bladder urothelium. Biomaterials, 2012, 33, 692-703.	5.7	31
315	Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis. Scientific Reports, 2015, 5, 15182.	1.6	31
316	TheBIRC6gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis. Oncotarget, 2014, 5, 6896-6908.	0.8	31
317	Chemosensitization of gemcitabineâ€resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the antiâ€apoptotic gene, clusterin. BJU International, 2009, 103, 384-390.	1.3	30
318	Hiding in Plain View: Genetic Profiling Reveals Decades Old Cross Contamination of Bladder Cancer Cell Line KU7 with HeLa. Journal of Urology, 2013, 190, 1404-1409.	0.2	30
319	The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer. Current Opinion in Urology, 2013, 23, 194-200.	0.9	30
320	Prostate Stromal Cells Express the Progesterone Receptor to Control Cancer Cell Mobility. PLoS ONE, 2014, 9, e92714.	1.1	30
321	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. European Urology, 2018, 74, 211-217.	0.9	30
322	Characterization of a Prostate- and Prostate Cancer-Specific Circular RNA Encoded by the Androgen Receptor Gene. Molecular Therapy - Nucleic Acids, 2019, 18, 916-926.	2.3	30
323	Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 322-331.e2.	0.9	30
324	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. JAMA Oncology, 2020, 6, e203187.	3.4	30

#	Article	IF	Citations
325	African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. Journal of Urology, 2020, 203, 727-733.	0.2	30
326	Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. PLoS ONE, 2017, 12, e0172048.	1.1	29
327	Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediateâ€risk disease. BJU International, 2012, 110, 821-827.	1.3	28
328	Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. PLoS ONE, 2015, 10, e0132343.	1.1	28
329	The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells. Journal of Biological Chemistry, 2015, 290, 20865-20879.	1.6	28
330	BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer. Clinical Cancer Research, 2017, 23, 1542-1551.	3.2	28
331	Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells. Cell Death and Disease, 2020, 11, 214.	2.7	28
332	Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Investigational New Drugs, 2002, 20, 145-158.	1.2	27
333	In Vitro and In Vivo Evaluation of Intravesical Docetaxel Loaded Hydrophobically Derivatized Hyperbranched Polyglycerols in an Orthotopic Model of Bladder Cancer. Biomacromolecules, 2011, 12, 949-960.	2.6	27
334	Expression and Function of Myometrial PSF Suggest a Role in Progesterone Withdrawal and the Initiation of Labor. Molecular Endocrinology, 2012, 26, 1370-1379.	3.7	27
335	Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian Journal of Andrology, 2013, 15, 342-349.	0.8	27
336	Clusterin Seals the Ocular Surface Barrier in Mouse Dry Eye. PLoS ONE, 2015, 10, e0138958.	1.1	27
337	Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma. Molecular Cancer Therapeutics, 2015, 14, 1024-1034.	1.9	27
338	Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis. EMBO Molecular Medicine, 2016, 8, 761-778.	3.3	27
339	Requirement of clusterin expression for prosurvival autophagy in hypoxic kidney tubular epithelial cells. American Journal of Physiology - Renal Physiology, 2016, 310, F160-F173.	1.3	27
340	The impact of time to metastasis on overall survival in patients with prostate cancer. World Journal of Urology, 2018, 36, 1039-1046.	1.2	27
341	Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression. Oncotarget, 2017, 8, 27966-27975.	0.8	27
342	Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. Oncotarget, 2014, 5, 7805-7819.	0.8	27

#	Article	IF	Citations
343	Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer. Clinical Cancer Research, 2020, 26, 1678-1689.	3.2	26
344	A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. Journal of Physical Education and Sports Management, 2017, 3, a001487.	0.5	25
345	SRRM4 gene expression correlates with neuroendocrine prostate cancer. Prostate, 2019, 79, 96-104.	1.2	25
346	A Model for the Design and Construction of a Resource for the Validation of Prognostic Prostate Cancer Biomarkers. Advances in Anatomic Pathology, 2013, 20, 39-44.	2.4	24
347	Novel targets and approaches in advanced prostate cancer. Current Opinion in Urology, 2007, 17, 182-187.	0.9	23
348	Therapeutic options in advanced prostate cancer: Present and future. Current Urology Reports, 2007, 8, 53-59.	1.0	23
349	Reduction of cold ischemiaâ€“reperfusion injury by graft-expressing clusterin in heart transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 819-826.	0.3	23
350	Validation of the prognostic value of NF-ÎºB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network. PLoS Medicine, 2019, 16, e1002847.	3.9	23
351	Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. , 1996, 78, 480-486.		22
352	Use of irinotecan for treatment of small cell carcinoma of the prostate. Prostate, 2011, 71, 675-681.	1.2	22
353	Radical prostatectomy in highâ€risk prostate cancer. International Journal of Urology, 2013, 20, 290-300.	0.5	22
354	Expression and role of the angiotensin II AT2 receptor in human prostate tissue: In search of a new therapeutic option for prostate cancer. Prostate, 2013, 73, 1057-1068.	1.2	22
355	Comparison of open and robotic-assisted prostatectomy: The University of British Columbia experience. Canadian Urological Association Journal, 2014, 8, 92.	0.3	22
356	Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptorâ€“Chromatin Interactions. Molecular Cancer Therapeutics, 2017, 16, 2281-2291.	1.9	22
357	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer and Prostatic Diseases, 2019, 22, 438-445.	2.0	22
358	Neonatal Renomegaly. Journal of Urology, 1987, 138, 1023-1027.	0.2	21
359	Consensus PP1 Binding Motifs Regulate Transcriptional Corepression and Alternative RNA Splicing Activities of the Steroid Receptor Coregulators, p54nrb and PSF. Molecular Endocrinology, 2011, 25, 1197-1210.	3.7	21
360	HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. Nature Communications, 2018, 9, 1431.	5.8	21

#	Article	IF	Citations
361	2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC). Canadian Urological Association Journal, 2019, 13, 307-314.	0.3	21
362	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. JAMA Oncology, 2021, 7, 1644.	3.4	21
363	Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4. Oncotarget, 2017, 8, 66878-66888.	0.8	21
364	Clusterin antisense complexed with chitosan for controlled intratumoral delivery. International Journal of Pharmaceutics, 2008, 350, 53-64.	2.6	20
365	Inhibition of DHCR24/Seladinâ€1 impairs cellular homeostasis in prostate cancer. Prostate, 2010, 70, 921-933.	1.2	20
366	Clonality Inference from Single Tumor Samples Using Low-Coverage Sequence Data. Journal of Computational Biology, 2017, 24, 515-523.	0.8	20
367	Identifying intermediate-risk candidates for active surveillance of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 605.e1-605.e8.	0.8	20
368	Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Canadian Urological Association Journal, 2017, 11, 16.	0.3	20
369	Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression. Oncotarget, 2015, 6, 20474-20484.	0.8	20
370	Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgenâ€independent progression. Prostate, 2011, 71, 525-537.	1.2	19
371	TP53INP1 overexpression in prostate cancer correlates with poor prognostic factors and is predictive of biological cancer relapse. Prostate, 2012, 72, 117-128.	1.2	19
372	Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. Prostate, 2016, 76, 1409-1419.	1.2	19
373	Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer. European Urology, 2018, 73, 949-960.	0.9	19
374	RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression. European Urology, 2019, 76, 157-166.	0.9	19
375	Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics. Frontiers in Oncology, 2020, 10, 633142.	1.3	19
376	SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer. Cancer Research, 2021, 81, 3664-3678.	0.4	19
377	Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. Journal of Urology, 2020, 204, 701-706.	0.2	19
378	MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. PLoS ONE, 2016, 11, e0165236.	1.1	19

#	Article	IF	Citations
379	Carbidopa abrogates <scp>L</scp>â€dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression. International Journal of Cancer, 2012, 130, 2835-2844.	2.3	18
380	Reduction in serum clusterin is a potential therapeutic biomarker in patients with castrationâ€resistant prostate cancer treated with custirsen. Cancer Medicine, 2013, 2, 468-477.	1.3	18
381	Functional mapping of androgen receptor enhancer activity. Genome Biology, 2021, 22, 149.	3.8	18
382	Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner. Oncotarget, 2017, 8, 9617-9633.	0.8	18
383	Regulation of AR mRNA translation in response to acute AR pathway inhibition. Nucleic Acids Research, 2022, 50, 1069-1091.	6.5	18
384	Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma. Neoplasia, 2015, 17, 805-816.	2.3	17
385	Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. European Urology, 2018, 73, 706-712.	0.9	17
386	Inhibition of endoplasmic reticulum chaperone protein glucose-regulated protein 78 potentiates anti-angiogenic therapy in renal cell carcinoma through inactivation of the PERK/eIF2Î± pathway. Oncotarget, 2015, 6, 34818-34830.	0.8	17
387	SARSâ€CoVâ€2 nucleocapsid protein interacts with immunoregulators and stress granules and phase separates to form liquid droplets. FEBS Letters, 2021, 595, 2872-2896.	1.3	17
388	Mutation of the Salt Bridge-forming Residues in the ETV6-SAM Domain Interface Blocks ETV6-NTRK3-induced Cellular Transformation. Journal of Biological Chemistry, 2013, 288, 27940-27950.	1.6	16
389	Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth. Molecular and Cellular Endocrinology, 2014, 384, 117-125.	1.6	16
390	Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor. Journal of Chemical Information and Modeling, 2016, 56, 2507-2516.	2.5	16
391	Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells. Cancer Letters, 2019, 449, 145-162.	3.2	16
392	Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer. Cancers, 2021, 13, 3488.	1.7	16
393	Metabolic heterogeneity signature of primary treatment-naÃ¯ve prostate cancer. Oncotarget, 2017, 8, 25928-25941.	0.8	16
394	Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. Oncotarget, 2018, 9, 6550-6561.	0.8	16
395	Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nature Communications, 2021, 12, 6377.	5.8	16
396	Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, e233-e236.	0.9	15

#	Article	IF	Citations
397	Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging. Canadian Urological Association Journal, 2018, 12, .	0.3	15
398	Systematic Identification and Characterization of RNA Editing in Prostate Tumors. PLoS ONE, 2014, 9, e101431.	1.1	15
399	A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor. Anti-Cancer Agents in Medicinal Chemistry, 2015, 15, 1333-1340.	0.9	15
400	CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation. Neoplasia, 2021, 23, 1147-1165.	2.3	15
401	Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer. Urologic Clinics of North America, 2012, 39, 517-531.	0.8	14
402	Validation of a sequential extraction and liquid chromatographyâ€“tandem mass spectrometric method for determination of dihydrotestosterone, androstanediol and androstanediolâ€“glucuronide in prostate tissues. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 902, 84-95.	1.2	14
403	Targeted therapy in prostate cancer. Histopathology, 2012, 60, 216-231.	1.6	14
404	Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro. Journal of Steroid Biochemistry and Molecular Biology, 2014, 144, 436-444.	1.2	14
405	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. BMC Urology, 2018, 18, 78.	0.6	14
406	Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. Journal of Urology, 2017, 197, 1026-1033.	0.2	13
407	Loss of Nuclear Functions of HOXA10 Is Associated With Testicular Cancer Proliferation. Frontiers in Oncology, 2018, 8, 594.	1.3	13
408	The molecular function of kallikreinâ€related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer. Molecular Oncology, 2020, 14, 105-128.	2.1	13
409	Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model. Oncology Reports, 2005, 13, 885-90.	1.2	13
410	Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptorâ€axis in castrationâ€resistant prostate tumors. Prostate, 2012, 72, 875-885.	1.2	12
411	Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundationâ€“Supported West Coast Prostate Cancer Dream Team. European Urology Focus, 2016, 2, 469-471.	1.6	12
412	Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 710-723.	3.2	12
413	Predicting complications following radical cystectomy with the ACS NSQIP universal surgical risk calculator. World Journal of Urology, 2020, 38, 1215-1220.	1.2	12
414	Steroidogenesis in Peripheral and Transition Zones of Human Prostate Cancer Tissue. International Journal of Molecular Sciences, 2021, 22, 487.	1.8	12

#	Article	IF	Citations
415	Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients. Cancers, 2021, 13, 2939.	1.7	12
416	Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget, 2016, 7, 40690-40703.	0.8	12
417	THEM6â€mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. EMBO Molecular Medicine, 2022, 14, e14764.	3.3	12
418	Decrease in donor heart injury by recombinant clusterin protein in cold preservation with University of Wisconsin solution. Surgery, 2012, 151, 364-371.	1.0	11
419	Transcriptomeâ€Based Analysis of Molecular Pathways for Clusterin Functions in Kidney Cells. Journal of Cellular Physiology, 2016, 231, 2628-2638.	2.0	11
420	Suppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression. Prostate, 2017, 77, 309-320.	1.2	11
421	Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models. Cancers, 2018, 10, 343.	1.7	11
422	GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression. Molecular Cancer Therapeutics, 2019, 18, 1811-1821.	1.9	11
423	Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. PLoS ONE, 2020, 15, e0237248.	1.1	11
424	Clusterin regulates macrophage expansion, polarization and phagocytic activity in response to inflammation in the kidneys. Immunology and Cell Biology, 2021, 99, 274-287.	1.0	11
425	Androgen receptor (AR) antagonism triggers acute succinateâ€mediated adaptive responses to reactivate AR signaling. EMBO Molecular Medicine, 2021, 13, e13427.	3.3	11
426	Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. Molecular Cancer Therapeutics, 2005, 4, 187-95.	1.9	11
427	TP53INP1 as new therapeutic target in castrationâ€resistant prostate cancer. Prostate, 2012, 72, 1286-1294.	1.2	10
428	Clonality Inference from Single Tumor Samples Using Low Coverage Sequence Data. Lecture Notes in Computer Science, 2016, , 83-94.	1.0	10
429	Quantification of large scale DNA organization for predicting prostate cancer recurrence. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2017, 91, 1164-1174.	1.1	10
430	Targeting Semaphorin 3C in Prostate Cancer With Small Molecules. Journal of the Endocrine Society, 2018, 2, 1381-1394.	0.1	10
431	Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2020, 26, 4616-4624.	3.2	10
432	Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clinical Cancer Research, 2020, 26, 6204-6214.	3.2	10

#	Article	IF	Citations
433	Design and Characterization of Injectable Poly(Lactic-Co-Glycolic Acid) Pastes for Sustained and Local Drug Release. Pharmaceutical Research, 2020, 37, 36.	1.7	10
434	Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies. Clinical Cancer Research, 2021, 27, 2340-2351.	3.2	10
435	Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene, 2022, 41, 125-137.	2.6	10
436	Modeling Androgen Deprivation Therapyâ€“Induced Prostate Cancer Dormancy and Its Clinical Implications. Molecular Cancer Research, 2022, 20, 782-793.	1.5	10
437	Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for â€œlargeâ€•cribriform prostatic adenocarcinoma. Modern Pathology, 2022, 35, 1092-1100.	2.9	10
438	Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects. Expert Review of Anticancer Therapy, 2005, 5, 1001-1009.	1.1	9
439	Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass. Oncotarget, 2015, 6, 22060-22071.	0.8	9
440	Development of 2-(5,6,7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer. Journal of Medicinal Chemistry, 2021, 64, 14968-14982.	2.9	9
441	Aneustat (OMN54) has aerobic glycolysisâ€inhibitory activity and also immunomodulatory activity as indicated by a firstâ€generation PDX prostate cancer model. International Journal of Cancer, 2018, 143, 419-429.	2.3	8
442	Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer. Molecular Cancer Therapeutics, 2020, 19, 2210-2220.	1.9	8
443	Assessment of quality of life (QOL), cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5036-5036.	0.8	8
444	A 2D-3D Registration Framework for Freehand TRUS-Guided Prostate Biopsy. Lecture Notes in Computer Science, 2015, , 272-279.	1.0	7
445	Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 5059-5059.	0.8	7
446	Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series. Canadian Urological Association Journal, 2011, 5, e156-e161.	0.3	7
447	Targeting the Androgen Receptorâ€”Theory and Practice. Urology, 2011, 78, S482-S484.	0.5	6
448	Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression. Journal of Urology, 2016, 196, 986-988.	0.2	6
449	Coâ€targeting driver pathways in prostate cancer: two birds with one stone. EMBO Molecular Medicine, 2018, 10, .	3.3	6
450	Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 316-323.	2.0	6

#	Article	IF	Citations
451	Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging. Canadian Urological Association Journal, 2018, 12, 270-275.	0.3	6
452	Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis. Human Pathology, 2022, 122, 84-91.	1.1	6
453	Novel targeted agents on the horizon for castration-resistant prostate cancer. Future Oncology, 2010, 6, 1883-1895.	1.1	5
454	Toward Predictive Signatures of Enzalutamide Response and Resistance. European Urology, 2015, 67, 61-63.	0.9	5
455	Clusterin Deficiency Predisposes C57BL/6j Mice to Cationic Bovine Serum Albumin-Induced Glomerular Inflammation . Journal of Inflammation Research, 2020, Volume 13, 969-983.	1.6	5
456	Long term deficiency of vitamin D in germ cell testicular cancer survivors. Oncotarget, 2018, 9, 21078-21085.	0.8	5
457	A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores. Pathology and Oncology Research, 2019, 25, 979-986.	0.9	4
458	Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 931.e9-931.e16.	0.8	4
459	A polymeric paste-drug formulation for local treatment of upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 194.e1-194.e7.	0.8	4
460	Continued 5Î±-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. Journal of Urology, 2019, 201, 106-112.	0.2	4
461	Novel non-AR therapeutic targets in castrate resistant prostate cancer. Translational Andrology and Urology, 2013, 2, 265-77.	0.6	4
462	MP31-09 IDENTIFICATION OF A RETRO-TRANSPOSON DERIVED GENE ASSOCIATED WITH PROGRESSION TO NEUROENDOCRINE PROSTATE CANCER.. Journal of Urology, 2014, 191, .	0.2	3
463	Prime Time for Intermittent Androgen Suppression. European Urology, 2014, 66, 240-242.	0.9	3
464	Subtle Protective Roles ofÂClusterin in Gastric Metaplasia After Acute Oxyntic Atrophy. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 246-250.e1.	2.3	3
465	A polymeric paste-drug formulation for intratumoral treatment of prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 324-332.	2.0	3
466	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. Cancer, 2022, 128, 269-274.	2.0	3
467	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. Journal of Urology, 2022, 207, 805-813.	0.2	3
468	Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. Cancer Medicine, 2022, , .	1.3	3

#	Article	IF	Citations
469	Next-Generation Sequencing of Prostate Tumors Provides Independent Evidence of Xenotropic Murine Leukemia Virus-Related Gammaretrovirus Contamination. Journal of Clinical Microbiology, 2012, 50, 536-537.	1.8	2
470	Apo J/clusterin expression and secretion: Evidence for 15-deoxy-Î”12,14-PGJ2-dependent mechanism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 335-342.	1.2	2
471	PARP inhibition in castration-resistant prostate cancer. Future Oncology, 2016, 12, 577-580.	1.1	2
472	Improving prostate cancer classification in H&E tissue micro arrays using Ki67 and P63 histopathology. Computers in Biology and Medicine, 2020, 127, 104053.	3.9	2
473	Molecular Mechanisms of Castrate Resistant Prostate Cancer. , 2013, , 43-64.		1
474	Good servants, poor masters. Canadian Urological Association Journal, 2014, 8, 163.	0.3	1
475	Motion and deformation compensation for freehand prostate biopsies. , 2014, , .		1
476	Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model. Targeted Oncology, 2017, 12, 69-79.	1.7	1
477	Abstract A12: Identification of pathways associated with abiraterone resistance in metastatic castration resistant prostate cancer: Preliminary results from the SU2C/AACR West Coast Prostate Cancer Dream Team. , 2015, , .		1
478	The functions of clusterin in renal mesenchymal stromal cells: Promotion of cell growth and regulation of macrophage activation. Experimental Cell Research, 2022, 413, 113081.	1.2	1
479	Re: Comparative Effectiveness of Minimally Invasive Versus Open Radical Prostatectomy. European Urology, 2010, 57, 1118-1119.	0.9	0
480	The E3ÂUbiquitin Ligase Siah2 Contributes to Castration-Resistant Prostate Cancer by Regulation of Androgen Receptor Transcriptional Activity. Cancer Cell, 2013, 23, 853.	7.7	0
481	Re: Robotic versus Open Prostatectomy: End of the Controversy. Journal of Urology, 2017, 197, 820-821.	0.2	0
482	Supplementary data: Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Canadian Urological Association Journal, 2017, 11, 62.	0.3	0
483	PSA screening: Time to overcome our brand confusion. Canadian Urological Association Journal, 2017, 11, 295-6.	0.3	0
484	Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE). European Urology, 2019, 75, 692-693.	0.9	0
485	Reply to Rodolfo Montironi, Liang Cheng, Marina Scarpelli, Alessia Cimadamore, Francesco Montorsi, and Antonio Lopez-Beltran's Letter to the Editor re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667â€“75: How Does Circulating DNA Reach the Blood Stream?. European Urology, 2019, 76, e73-e74.	0.9	0
486	B2B: Prostate Cancer. SociÃ©tÃ© Internationale D'urologie Journal, 2021, 2, S30-S50.	0.2	0

#	Article	IF	Citations
487	Cell Biology of Prostate Cancer and Molecular Targets. , 2010, , 1-24.		0
488	Clusterin as a Target for Treatment of Castration-Resistant Prostate Cancer. , 2013, , 329-340.		0
489	Co-targeting Adaptive Survival Pathways. Current Clinical Urology, 2014, , 233-248.	0.0	0
490	Chemotherapeutic Agents for Urologic Oncology: Basic Principles. , 2020, , 611-637.		0